| Title： | Chinese Guidelines on Perioperative Management of Resectable Esophageal Cancer (2022) |
| Edition： | Original |
| Classification： | Standard guideline |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Healthcare personnel at all levels involved in the perioperative management of esophageal cancer. |
| Evidence classification method： | This systematic review–based guideline was developed by a multidisciplinary Expert Panel that included the NCC writing committee members, who performed comprehensive literature searches and developed recommendations based on the literature review. The Expert Panel had one in-person meeting, conducted other meetings via teleconference and/or webinar, and corresponded through e-mail. Based on the consideration of the evidence, the authors were asked to contribute to the development of the guideline, provide critical review, and finalize the guideline recommendations. Members of the Expert Panel were responsible for reviewing and approving the penultimate version of the guideline, which was then circulated for open comment before submission for editorial review and consideration for publication. The CATS Esophageal Surgery Committee members, CSTCVS Esophageal Disease Panelists and CSDE members graded the evidence supporting the recommendations and assessed the risk-benefit profile for each recommendation. A scheduled teleconference was used to organize the topics covered by the guideline and review the proposed recommendations, and subsequent teleconferences were then held to vote on the final recommendations formally. Acceptance for the final recommendations required greater than 75% approval of each of the recommendations. Certainty of the evidence (i.e., evidence quality) for each outcome was assessed using the Cochrane Risk of Bias tool and elements of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) quality assessment and recommendations development process. GRADE quality assessment labels (i.e., high, moderate, low, very low) were assigned for each outcome by the project methodologist in collaboration with the Expert Panel co-chairs and reviewed by the full Expert Panel. |
| Development unit： | National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College; Chinese Association of Thoracic Surgeons; Chinese Society for Thoracic and Cardiovascular Surgery; Chinese Society for Diseases of the Esophagus |
| Registration time: | 2022-07-03 |
| Registration number： | IPGRP-2022CN377 |
| Purpose of the guideline: | Esophagogastric cancer is an aggressive tumor with a significant global burden, especially in China. There is no international consensus on the optimal management of resectable esophageal cancer. To develop an evidence-based clinical practice guideline to assist in clinical decision-making, the Chinese National Cancer Center (NCC), Chinese Association of Thoracic Surgeons (CATS), Chinese Society for Thoracic and Cardiovascular Surgery (CSTCVS), and Chinese Society for Diseases of the Esophagus (CSDE) jointly convened an Expert Panel to conduct a systematic review of the more recently published literature (2000-2022) on perioperative management options for patients with resectable esophageal cancer and provide recommended care options for this patient population. |
Latest registration
